Softwr

Research · head to head

Dotmatics vs Medidata Rave

Dotmatics logo

Dotmatics

Research

Research informatics group behind GraphPad Prism, SnapGene, Geneious and LabArchives, now owned by Siemens

From
On request
Rated
-
Full reviewWebsite
Medidata Rave logo

Medidata Rave

Research

Electronic data capture for regulated clinical trials, sold only through a sales process

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Dotmatics the portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.; Medidata Rave no pricing is published at all, so a first time sponsor cannot budget a study without entering a sales process and usually cannot benchmark the quote against anything.
  • They diverge on capability: Dotmatics covers Dotmatics platform, Medidata Rave covers Case report form design.
  • Prices and features above were last checked on 31 August 2026.

Where they differ

Only the attributes on which Dotmatics and Medidata Rave actually diverge.

Attributes where Dotmatics and Medidata Rave differ
AttributeDotmaticsMedidata Rave
PlatformsWeb, Windows, macOS, On-premiseWeb

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Research).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Dotmatics

  • Dotmatics platform
  • GraphPad Prism
  • SnapGene
  • Geneious Prime and Biologics
  • LabArchives
  • Flow cytometry tools
  • Protein Metrics
  • Siemens ownership

Only in Medidata Rave

  • Case report form design
  • Edit checks and queries
  • Part 11 audit trail
  • Rave Lite
  • Coding and safety
  • Platform integrations

What people use each for

The jobs each tool is most often brought in to do.

Dotmatics

  • A pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layernot Medidata Rave
  • A biotech that already owns Prism, SnapGene and Geneious separately and wants to understand what a group contract would covernot Medidata Rave
  • A university licensing LabArchives across departments as an institutional electronic lab notebooknot Medidata Rave
  • A biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement routenot Medidata Rave

Medidata Rave

  • A sponsor running a registrational Phase III study where inspection readiness and a validated audit trail are non negotiablenot Dotmatics
  • A biotech that wants its CRO to run data management and benefits from the CRO already having Rave trained staff and templatesnot Dotmatics
  • A sponsor standardising forms across a programme so that a global library is reused rather than each study being built from scratchnot Dotmatics
  • A device or Phase IV study where Rave Lite gives the same compliance posture at a lower configuration burdennot Dotmatics

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Dotmatics

  • The portfolio was assembled by acquisition and integration between the constituent products is uneven, so buying several Dotmatics brands does not deliver a single connected environment and often means the same manual export steps as before.
  • The Siemens acquisition completed in July 2025 with stated revenue synergy targets, which usually translates into pressure to move individually bought desktop licences into larger platform agreements, and small buyers of a single Prism or SnapGene seat should expect that pressure at renewal.
  • Nothing about the enterprise platform is publicly priced, and even the individual applications are increasingly moved to subscription, so total cost across a research group is hard to establish before negotiation.
  • Each acquired product retains its own licence terms, support channel and release cycle, so an organisation using four Dotmatics brands manages four different renewal dates, entitlement models and support experiences.
  • Enterprise deployments require data migration and configuration services, and validated instances for regulated use add both cost and an ongoing customer revalidation duty after each release, so the informatics platform is a programme rather than a purchase.

Medidata Rave

  • No pricing is published at all, so a first time sponsor cannot budget a study without entering a sales process and usually cannot benchmark the quote against anything.
  • Cost is dominated by study build rather than licence, and every protocol amendment that changes a form triggers billable rework, so a study with unstable protocols costs far more than the initial quote implied.
  • Configuration requires trained specialists, so most sponsors cannot build a study in house and are dependent on Medidata professional services or a CRO, which lengthens startup.
  • The system assumes a professional clinical data management function; a small sponsor without data managers will not operate it directly and will pay a CRO to do so.
  • Deep use of the wider Medidata platform for randomisation, imaging and patient reported data creates commercial lock in, because moving EDC later means unpicking integrations that were bought as one bundle.

Pricing, plan by plan

Dotmatics

On request
  • Dotmatics platform$undefined/year
    • Enterprise informatics platform priced per user per year on quotation
    • Chemistry and biology registration, assay data and ELN modules scoped separately
    • Implementation and data migration services quoted as a separate programme

Medidata Rave

On request
  • Medidata Rave EDC$undefined/year
    • Priced per study through a sales process
    • Study build and configuration charged separately from licence
    • Mid study amendments generally billable

Which should you pick?

Choose Dotmatics if

  • You need dotmatics platform.
  • You work on Web, Windows, macOS, On-premise.
  • You also want graphpad prism.
Dotmatics review

Choose Medidata Rave if

  • You need case report form design.
  • You also want edit checks and queries.
Medidata Rave review

Questions people ask

Is Dotmatics or Medidata Rave better?
Neither clearly leads. Dotmatics starts at On request and Medidata Rave at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Dotmatics or Medidata Rave?
Dotmatics starts at On request and Medidata Rave at On request.
Does Dotmatics or Medidata Rave run on more platforms?
Dotmatics runs on Web, Windows, macOS, On-premise. Medidata Rave runs on Web.
What is Dotmatics best used for?
Dotmatics is most often used for a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer, a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover, a university licensing labarchives across departments as an institutional electronic lab notebook, a biologics group needing sequence analysis, flow cytometry and proteomics tools from one supplier with a single procurement route. Of those, a pharmaceutical company consolidating compound registration, assay data and biology screening onto one informatics layer and a biotech that already owns prism, snapgene and geneious separately and wants to understand what a group contract would cover are not what Medidata Rave is typically brought in for.
What can Dotmatics do that Medidata Rave cannot?
Dotmatics covers Dotmatics platform, GraphPad Prism, SnapGene, Geneious Prime and Biologics. Medidata Rave covers Case report form design, Edit checks and queries, Part 11 audit trail, Rave Lite.

Answered from the vendors’ own pages

Dotmatics: Who owns Dotmatics?

Siemens, which completed a 5.1 billion dollar acquisition on 1 July 2025. Dotmatics now sits inside Siemens Digital Industries Software.

Medidata Rave: Who owns Medidata?

Dassault Systemes, which acquired Medidata in 2019. Rave is sold as part of the Dassault life sciences portfolio.

Dotmatics: Is GraphPad Prism a Dotmatics product?

Yes. So are SnapGene, Geneious, LabArchives, FCS Express, OMIQ, Protein Metrics, SoftGenetics and nQuery.

Medidata Rave: How is Rave priced?

Per study, through a sales process. Nothing is published, and study build and amendments are charged separately from the licence.

Dotmatics: Do the products work together?

To varying degrees. They were acquired separately and integration across the portfolio is uneven, so verify the specific pair you care about before assuming it.

Medidata Rave: Is Rave validated out of the box?

Medidata supplies validation and qualification documentation, but the sponsor still owns study level user acceptance testing and its own validation evidence.

Dotmatics: Is enterprise pricing published?

No. The informatics platform is quoted per user per year with modules and services scoped separately.

Medidata Rave: What is Rave Lite for?

Lower complexity studies, typically Phase I, Phase IV and medical device, where a full study build is not justified.

Share

Related pages

More on Dotmatics

More on Medidata Rave

Keep looking

Other head to heads